These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 11353333)

  • 1. Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism.
    Shachter NS
    Curr Opin Lipidol; 2001 Jun; 12(3):297-304. PubMed ID: 11353333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insights into apolipoprotein C metabolism from transgenic and gene-targeted mice.
    Jong MC; Havekes LM
    Int J Tissue React; 2000; 22(2-3):59-66. PubMed ID: 10937355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibitory effects of specific apolipoprotein C-III isoforms on the binding of triglyceride-rich lipoproteins to the lipolysis-stimulated receptor.
    Mann CJ; Troussard AA; Yen FT; Hannouche N; Najib J; Fruchart JC; Lotteau V; André P; Bihain BE
    J Biol Chem; 1997 Dec; 272(50):31348-54. PubMed ID: 9395464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Further characterization of the metabolic properties of triglyceride-rich lipoproteins from human and mouse apoC-III transgenic mice.
    Aalto-Setälä K; Weinstock PH; Bisgaier CL; Wu L; Smith JD; Breslow JL
    J Lipid Res; 1996 Aug; 37(8):1802-11. PubMed ID: 8864964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of lipoprotein lipase and hepatic lipase on the transformation of VLDL and HDL during lipolysis of VLDL.
    Murdoch SJ; Breckenridge WC
    Atherosclerosis; 1995 Dec; 118(2):193-212. PubMed ID: 8770314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway.
    Sehayek E; Eisenberg S
    J Biol Chem; 1991 Sep; 266(27):18259-67. PubMed ID: 1917954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apolipoprotein C-III and the metabolic basis for hypertriglyceridemia and the dense low-density lipoprotein phenotype.
    Zheng C; Khoo C; Furtado J; Sacks FM
    Circulation; 2010 Apr; 121(15):1722-34. PubMed ID: 20368524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipoprotein distribution of apolipoprotein C-III and its relationship to the presence in plasma of triglyceride-rich remnant lipoproteins.
    Marcoux C; Tremblay M; Fredenrich A; Davignon J; Cohn JS
    Metabolism; 2001 Jan; 50(1):112-9. PubMed ID: 11172484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apolipoprotein C-I modulates the interaction of apolipoprotein E with beta-migrating very low density lipoproteins (beta-VLDL) and inhibits binding of beta-VLDL to low density lipoprotein receptor-related protein.
    Weisgraber KH; Mahley RW; Kowal RC; Herz J; Goldstein JL; Brown MS
    J Biol Chem; 1990 Dec; 265(36):22453-9. PubMed ID: 2266137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural peculiarities of the binding of very low density lipoproteins and low density lipoproteins to the LDL receptor in hypertriglyceridemia: role of apolipoprotein E.
    Dergunov AD; Smirnova EA; Merched A; Visvikis S; Siest G; Yakushkin VV; Tsibulsky V
    Biochim Biophys Acta; 2000 Feb; 1484(1):29-40. PubMed ID: 10685028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apolipoproteins C-II and C-III inhibit selective uptake of low- and high-density lipoprotein cholesteryl esters in HepG2 cells.
    Huard K; Bourgeois P; Rhainds D; Falstrault L; Cohn JS; Brissette L
    Int J Biochem Cell Biol; 2005 Jun; 37(6):1308-18. PubMed ID: 15778093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors.
    Gordts PL; Nock R; Son NH; Ramms B; Lew I; Gonzales JC; Thacker BE; Basu D; Lee RG; Mullick AE; Graham MJ; Goldberg IJ; Crooke RM; Witztum JL; Esko JD
    J Clin Invest; 2016 Aug; 126(8):2855-66. PubMed ID: 27400128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Very low-density lipoprotein/lipo-viro particles reverse lipoprotein lipase-mediated inhibition of hepatitis C virus infection via apolipoprotein C-III.
    Sun HY; Lin CC; Lee JC; Wang SW; Cheng PN; Wu IC; Chang TT; Lai MD; Shieh DB; Young KC
    Gut; 2013 Aug; 62(8):1193-203. PubMed ID: 22689516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [THE LIPOLYSIS IN PHYLOGENETICALLY EARLY LIPOPROTEINS OF LOW DENSITY AND MORE LATER LIPOPROTEINS OF VERY LOW DENSITY: FUNCTION AND DIAGNOSTIC VALUE OF APOE AND APOC-III].
    Rozhkova TA; Titov VN; Amelyushkina VA; Kaba SI; Kukhartchuk VV
    Klin Lab Diagn; 2015 Dec; 60(12):4-14. PubMed ID: 27032246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of human apolipoprotein C-III in transgenic mice results in an accumulation of apolipoprotein B48 remnants that is corrected by excess apolipoprotein E.
    de Silva HV; Lauer SJ; Wang J; Simonet WS; Weisgraber KH; Mahley RW; Taylor JM
    J Biol Chem; 1994 Jan; 269(3):2324-35. PubMed ID: 8294490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The composition, structural properties and binding of very-low-density and low-density lipoproteins to the LDL receptor in normo- and hypertriglyceridemia: relation to the apolipoprotein E phenotype.
    Dergunov AD; Novoselov AV; Visvikis S; Siest G; Yakushkin VV; Tsibulsky V
    Biol Chem; 2005 May; 386(5):441-52. PubMed ID: 15927888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human ApoA-II inhibits the hydrolysis of HDL triglyceride and the decrease of HDL size induced by hypertriglyceridemia and cholesteryl ester transfer protein in transgenic mice.
    Zhong S; Goldberg IJ; Bruce C; Rubin E; Breslow JL; Tall A
    J Clin Invest; 1994 Dec; 94(6):2457-67. PubMed ID: 7989603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The crucial roles of apolipoproteins E and C-III in apoB lipoprotein metabolism in normolipidemia and hypertriglyceridemia.
    Sacks FM
    Curr Opin Lipidol; 2015 Feb; 26(1):56-63. PubMed ID: 25551803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atorvastatin decreases apolipoprotein C-III in apolipoprotein B-containing lipoprotein and HDL in type 2 diabetes: a potential mechanism to lower plasma triglycerides.
    Dallinga-Thie GM; Berk-Planken II; Bootsma AH; Jansen H;
    Diabetes Care; 2004 Jun; 27(6):1358-64. PubMed ID: 15161788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human apolipoprotein A-II determines plasma triglycerides by regulating lipoprotein lipase activity and high-density lipoprotein proteome.
    Julve J; Escolà-Gil JC; Rotllan N; Fiévet C; Vallez E; de la Torre C; Ribas V; Sloan JH; Blanco-Vaca F
    Arterioscler Thromb Vasc Biol; 2010 Feb; 30(2):232-8. PubMed ID: 19910634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.